Acute effect of antiseizure drugs on background oscillations in Scn1aA1783V Dravet syndrome mouse model

被引:2
|
作者
Quinn, Shir [1 ,2 ]
Brusel, Marina [1 ]
Ovadia, Mor [1 ,3 ]
Rubinstein, Moran [1 ,2 ,3 ]
机构
[1] Tel Aviv Univ, Goldschleger Eye Res Inst, Sackler Fac Med, Tel Aviv, Israel
[2] Tel Aviv Univ, Sackler Fac Med, Dept Human Mol Genet & Biochem, Tel Aviv, Israel
[3] Tel Aviv Univ, Sagol Sch Neurosci, Tel Aviv, Israel
基金
以色列科学基金会;
关键词
Dravet syndrome; background oscillations; mouse model; antiseizure; spectral modulation; SEVERE MYOCLONIC EPILEPSY; EEG; MECHANISMS; COMORBIDITIES; OXCARBAZEPINE; CARBAMAZEPINE; INTERNEURONS; LAMOTRIGINE; STIRIPENTOL; VALPROATE;
D O I
10.3389/fphar.2023.1118216
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Dravet syndrome (Dravet) is a rare and severe form of developmental epileptic encephalopathy. Antiseizure medications (ASMs) for Dravet patients include valproic acid (VA) or clobazam (CLB), with or without stiripentol (STP), while sodium channel blockers like carbamazepine (CBZ) or lamotrigine (LTG) are contraindicated. In addition to their effect on epileptic phenotypes, ASMs were shown to modify the properties of background neuronal activity. Nevertheless, little is known about these background properties alterations in Dravet. Here, utilizing Dravet mice (DS, Scn1a (A1783V/WT)), we tested the acute effect of several ASMs on background electrocorticography (ECoG) activity and frequency of interictal spikes. Compared to wild-type mice, background ECoG activity in DS mice had lower power and reduced phase coherence, which was not corrected by any of the tested ASMs. However, acute administration of Dravet-recommended drugs, VA, CLB, or a combination of CLB + STP, caused, in most mice, a reduction in the frequency of interictal spikes, alongside an increase in the relative contribution of the beta frequency band. Conversely, CBZ and LTG increased the frequency of interictal spikes, with no effect on background spectral properties. Moreover, we uncovered a correlation between the reduction in interictal spike frequency, the drug-induced effect on the power of background activity, and a spectral shift toward higher frequency bands. Together, these data provide a comprehensive analysis of the effect of selected ASMs on the properties of background neuronal oscillations, and highlight a possible correlation between their effect on epilepsy and background activity.
引用
收藏
页数:13
相关论文
共 33 条
  • [1] Dravet Variant SCN1AA1783V Impairs Interneuron Firing Predominantly by Altered Channel Activation
    Layer, Nikolas
    Sonnenberg, Lukas
    Gonzalez, Emilio Pardo
    Benda, Jan
    Hedrich, Ulrike B. S.
    Lerche, Holger
    Koch, Henner
    Wuttke, Thomas, V
    FRONTIERS IN CELLULAR NEUROSCIENCE, 2021, 15
  • [2] Proteomic signature of the Dravet syndrome in the genetic Scn1a-A1783V mouse model
    Miljanovic, Nina
    Hauck, Stefanie M.
    van Dijk, R. Maarten
    Di Liberto, Valentina
    Rezaei, Ali
    Potschka, Heidrun
    NEUROBIOLOGY OF DISEASE, 2021, 157
  • [3] Effect of a combination therapy with cannabidiol and β-caryophyllene in SCN1A-A1783V mice, an experimental model of dravet syndrome
    Alonso Gomez, C.
    Satta, V.
    Hernandez Fisac, I.
    Fernandez Ruiz, J.
    Sagredo Ezkioga, O.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2021, 53 : S259 - S260
  • [4] Ictal vocalizations in the Scn1a+/- mouse model of Dravet syndrome
    Anderson, Lyndsey L.
    Everett-Morgan, Declan
    Petkova, Stela P.
    Silverman, Jill L.
    Arnold, Jonathon C.
    EPILEPSIA OPEN, 2023, 8 (03) : 776 - 784
  • [5] Adolescent behavioral abnormalities in a Scn1a+/- mouse model of Dravet syndrome
    Bahceci, Dilara
    Anderson, Lyndsey Leigh
    Brown, Cassandra Veronica Occelli Hanbury
    Zhou, Cilla
    Arnold, Jonathon Carl
    EPILEPSY & BEHAVIOR, 2020, 103
  • [6] Defects of Oligodendrocyte Migration in the Scn1b-/- Mouse Model of Dravet Syndrome
    Clemons, Krisyah
    O'Malley, Heather A.
    Isom, Lori L.
    FASEB JOURNAL, 2019, 33
  • [7] Astrocyte Ca2+signaling is facilitated in Scn1a+/- mouse model of Dravet syndrome
    Uchino, Kouya
    Tanaka, Yasuyoshi
    Ikezawa, Wakana
    Deshimaru, Masanobu
    Kubota, Kaori
    Watanabe, Takuya
    Katsurabayashi, Shutaro
    Iwasaki, Katsunori
    Hirose, Shinichi
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2023, 643 : 169 - 174
  • [8] Disease-modifying effects of cannabidiol, β-caryophyllene and their combination in Syn1-Cre/Scn1aWT/A1783V mice, a preclinical model of Dravet syndrome
    Alonsoa, Cristina
    Sattaa, Valentina
    Hernandez-Fisac, Ines
    Fernandez-Ruiz, Javier
    Sagredo, Onintza
    NEUROPHARMACOLOGY, 2023, 237
  • [9] Scn1a gene reactivation after symptom onset rescues pathological phenotypes in a mouse model of Dravet syndrome
    Nicholas Valassina
    Simone Brusco
    Alessia Salamone
    Linda Serra
    Mirko Luoni
    Serena Giannelli
    Simone Bido
    Luca Massimino
    Federica Ungaro
    Pietro Giuseppe Mazzara
    Patrizia D’Adamo
    Gabriele Lignani
    Vania Broccoli
    Gaia Colasante
    Nature Communications, 13
  • [10] Anticonvulsant effects of the natural products magnolol and amorfrutin-2 in the Scn1a+/-mouse model of Dravet syndrome
    Yip, K. L.
    Sharman, L. A.
    Anderson, L. L.
    Kevin, R. C.
    Arnold, J. C.
    EPILEPSIA, 2023, 64 : 21 - 22